Apyx Medical Corporation Common Stock (APYX) — Analysis Summary
Apyx Medical Corporation Common Stock (APYX) has a market cap of $179.39M with year-over-year revenue growth of +9.9%. Net margin stands at -21.2%. The stock trades at a P/E ratio of -19.6.
Key Takeaways
- Revenue changed +9.9% year-over-year
- Net margin of -21.2%
- P/E ratio of -19.6
Compared to other companies in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector, APYX posted revenue growth of +9.9% and trades at a P/E of -19.6.
Apyx Medical Corporation Common Stock (APYX)
UPDATED — ET · SOURCE POLYGON
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Interest coverage at -0.8x — earnings do not cover interest payments
The latest filing shows negative free cash flow.
Apyx Medical Corp is an energy technology medical device company. It specializes in developing, manufacturing, and marketing a range of cosmetic and surgical products and technologies, as well as related medical products used in doctor's offices, surgery centers, and hospitals. Its product offerings comprise Renuvion cosmetic technology, which offers plastic surgeons, facial plastic surgeons, and cosmetic physicians the ability to provide controlled heat to the tissue to achieve desired results. The J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminates unintended tissue trauma. It operates in two segments namely: Surgical Aesthetics and Original Equipment Manufacturing (OEM). Its Surgical Aesthetics segment derives the majority of its revenue.
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Employees
205
Headquarters
CLEARWATER, FL
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.